Galectins have been extensively linked to cancer, specifically controlling cell transformation, apoptosis, proliferation, migration, invasion, and angiogenesis (40), and LGALS1 has been previously documented to enhance the survival of hematological malignancies by directly targeting tumor cells (41). Here, LGALS1 is linked to hematologic disorder.